Claims
- 1. A compound of formula (I)
- 2. The compound of claim 1, wherein
R1 is —O-alkyl or —S-alkyl; R2 is hydrogen; and R3 is hydrogen; or a pharmaceutically acceptable salt thereof.
- 3. The compound of claim 2 selected from,
1-[4-(4-{2-[2-(4-Methoxy-phenyl)-vinyl]-oxazol-4-ylmethoxy}-phenyl)-butyl]-1H-[1,2,3]triazole; 1-[4-(4-{2-[2-(4-Trifluoromethoxy-phenyl)-vinyl]-oxazol-4-ylmethoxy}-phenyl)-butyl]-1H-[1,2,3]triazole; 1-[4-(4-{2-[2-(4-Difluoromethoxy-phenyl)-vinyl]-oxazol-4-ylmethoxy}-phenyl)-butyl]-1H-[1,2,3]triazole; and 1-[4-(4-{2-[2-(4-Trifluoromethylsulfanyl-phenyl)-vinyl]-oxazol-4-ylmethoxy}-phenyl)-butyl]-1H-[1,2,3]triazole.
- 4. The compound of claim 1, wherein
R1 is —O-alkyl or —S-alkyl; R2 is halogen; and R3 is hydrogen; or a pharmaceutically acceptable salt thereof.
- 5. The compound of claim 4, which is
1-[4-(4-{2-[2-(2-Fluoro-4-trifluoromethoxy-phenyl)-vinyl]-oxazol-4-ylmethoxy}-phenyl)-butyl]-1H-[1,2,3]triazole.
- 6. The compound of claim 1, wherein
R1 and R2 together with the carbon atoms to which they are attached form a 5 or 6 membered heterocyclic ring; and R3 is hydrogen; or a pharmaceutically acceptable salt thereof.
- 7. The compound of claim 6 which is selected from
1-(4-{4-[2-(2-Benzo[1,3]dioxol-5-yl-vinyl)-oxazol-4-ylmethoxy]-phenyl}-butyl)-1H-[1,2,3]triazole; 1-[4-(4-{2-[2-(2,2-Difluoro-benzo[1,3]dioxol-5-yl)-vinyl]-oxazol-4-ylmethoxy}-phenyl)-butyl]-1H-[1,2,3]triazole; and 6-(2-{4-[4-(4-[1,2,3]Triazol-1-yl-butyl)-phenoxymethyl]-oxazol-2-yl}-vinyl)-1H-benzoimidazole.
- 8. The compound of claim 1, wherein
R1 and R2 together with the carbon atoms to which they are attached form a 5 or 6 membered heterocyclic ring; and R3 is halogen; or a pharmaceutically acceptable salt thereof.
- 9. The compound of claim 8 which is selected from
1-[4-(4-{2-[2-(2,2,6-Trifluoro-benzo[1,3]dioxol-5-yl)-vinyl]-oxazol-4-ylmethoxy}-phenyl)-butyl]-1H-[1,2,3]triazole; and 1-[4-(4-{2-[2-(2,2,4-Trifluoro-benzo[1,3]dioxol-5-yl)-vinyl]-oxazol-4-ylmethoxy}-phenyl)-butyl]-1H-[1,2,3]triazole.
- 10. The compound of claim 1 which is selected from
1-[4-(4-{2-[2-(4-Trifluoromethoxy-phenyl)-vinyl]-oxazol-4-ylmethoxy}-phenyl)-butyl]-1H-[1,2,3]triazolium methanesulfonate, 1-[4-(4-{2-[2-(4-Trifluoromethoxy-phenyl)-vinyl]-oxazol-4-ylmethoxy}-phenyl)-butyl]-1H-[1,2,3]triazolium p-toluenesulfonate, and 1-[4-(4-{2-[2-(4-Trifluoromethoxy-phenyl)-vinyl]-oxazol-4-ylmethoxy}-phenyl)-butyl]-1H-[1,2,3]triazolium chloride.
- 11. A process for the manufacture of a compound of claim 1, wherein
(a) a compound of formula (V) 7is reacted with a compound of formula (IV) 8
- 12. The process of claim 11 further comprising isolating the compound of formula (I) from the reaction mixture.
- 13. The process of claim 12 further comprising converting a compound of formula I to a pharmaceutically acceptable salt.
- 14. A pharmaceutical composition, comprising one or more compounds of claim 1 and a pharmaceutically acceptable excipient.
- 15. A method of treating or controlling cancer comprising administering to a patient in need of such therapy a therapeutically effective amount of at least one compound according to claim 1.
- 16. The method of claim 15 for the treatment or control of breast, lung, colon and prostate tumors.
Priority Claims (1)
Number |
Date |
Country |
Kind |
03 007 124.5 |
Mar 2003 |
EP |
|
PRIORITY TO RELATED APPLICATIONS
[0001] This application claims the benefit of Provisional Application Serial No. 60/459,741, filed Apr. 2, 2003.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60459741 |
Apr 2003 |
US |